Literature DB >> 10501358

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.

N M Makridakis1, R K Ross, M C Pike, L E Crocitto, L N Kolonel, C L Pearce, B E Henderson, J K Reichardt.   

Abstract

BACKGROUND: Prostate cancer is a very common disease in more-developed countries, but its cause is largely unknown. It is an androgen-dependent cancer, and androgens have been proposed as having a substantial role in predisposition to the disease. Thus, variations in androgen metabolism genes may affect risk of this disease.
METHODS: We screened 216 African-American and 172 Hispanic men with prostate cancer, and 261 African-American and 200 Hispanic healthy men (controls), from a large prospective cohort study (the Hawaii-Los Angeles Multiethnic Cohort Study) for a mis-sense substitution in the human prostatic (or type II) steroid 5alpha-reductase (SRD5A2) gene, the product of which controls metabolic activation of testosterone to dihydrotestosterone. This mis-sense substitution results in an alanine residue at codon 49 being replaced with threonine (A49T). We also reconstructed this mutation in the SRD5A2 cDNA, and overexpressed the enzyme in mammalian tissue culture cells.
FINDINGS: The A49T aminoacid substitution in the SRD5A2 gene increased the risk of clinically significant disease 7.2-fold in African-American men (95% CI=2.17-27.91; p=0.001) and 3.6-fold in Hispanic men (1.09-12.27; p=0.04). The mutant enzyme had a higher in-vitro Vmax than the normal enzyme (9.9 vs 1.9 nmol min(-1) mg(-1)).
INTERPRETATION: The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles. We estimate that the population attributable risk due to this aminoacid substitution for clinically significant disease is about 8% in both populations. Increased conversion of testosterone to dihydrotestosterone catalysed by this variant steroid 5alpha-reductase enzyme may be the cause of the increased risk.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501358     DOI: 10.1016/S0140-6736(98)11282-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  55 in total

1.  Sample size in pilot genetic studies.

Authors:  Terry Hyslop
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

2.  A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.

Authors:  R A Kittles; A B Baffoe-Bonnie; T Y Moses; C M Robbins; C Ahaghotu; P Huusko; C Pettaway; S Vijayakumar; J Bennett; G Hoke; T Mason; S Weinrich; J M Trent; F S Collins; S Mousses; J Bailey-Wilson; P Furbert-Harris; G Dunston; I J Powell; J D Carpten
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

3.  Polymorphic changes in the KAL1 gene: not all of them should be classified as polymorphisms.

Authors:  D Söderlund; F Vilchis; J P Méndez
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

4.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 5.  Risk factors for prostate cancer.

Authors:  Amit R Patel; Eric A Klein
Journal:  Nat Clin Pract Urol       Date:  2009-02

6.  No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.

Authors:  C Leigh Pearce; David J Van Den Berg; Nick Makridakis; Juergen K V Reichardt; Ronald K Ross; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson
Journal:  Hum Mol Genet       Date:  2008-05-10       Impact factor: 6.150

7.  [Genotype of the GNB3 C825T polymorphism, A risk factor for the development and course of prostate cancer?].

Authors:  A Eisenhardt; A Scherag; M Kempin; K H Jöckel; H Rübben
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 8.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

9.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

10.  Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis.

Authors:  Vincent L Freeman; Ramon Durazo-Arvizu; LaShon C Keys; Marc P Johnson; Kristian Schafernak; Vikas K Patel
Journal:  Am J Public Health       Date:  2004-05       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.